Physician profile
Margaret Mantz
NPI 1679915672
$7,579.58
in general payments reported to CMS, 2019-2025
17 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $1,224 · 2023: $924 · 2024: $2,838 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476 · Travel and Lodging: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,476.32 |
| Travel and Lodging | $1,592.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $1,861.36 | 2024-2025 | Evoke |
| Nevro Corp. | $1,411.48 | 2021-2024 | Senza |
| Boston Scientific Corporation | $1,090.25 | 2021-2025 | General - Dbs, General - Pain Management |
| Abbott Laboratories | $842.45 | 2022-2025 | Infinity, Proclaim |
| Baxter Healthcare | $839.46 | 2022-2025 | Actifuse |
| Nalu Medical, INC. | $572.05 | 2025 | Nalu Neurostimulation System |
| Globus Medical, INC. | $540.68 | 2025 | Senza |
| Relievant Medsystems, INC. | $124.84 | 2022 | |
| Medtronic, INC. | $83.09 | 2023 | Synchromedii |
| Orthofix Medical, INC. | $37.52 | 2024 | Spinal-Stim |
| Tandem Diabetes Care, INC. | $29.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cala Health, INC. | $28.36 | 2025 | Cala Kiq |
| Abbvie INC. | $27.31 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.76 | 2022 | |
| Dynavax Technologies Corporation | $25.03 | 2023 | Heplisav-B |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuros Medical, INC. | $22.54 | 2025 | Altius |
| Glaxosmithkline, LLC. | $18.40 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Mantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.